Skip to main content

A simple blood test to choose the best treatment for each patient with depression.

Project description

A blood test for antidepressant medication choice

Treatment of major depressive disorder is based on a trial-and-error approach, with patients trying several different medications and often without the desired response. This has a huge socioeconomic impact affecting millions of people who struggle to recover. Funded by the European Innovation Council, the RxMine project introduces a novel platform to assist the search of the best antidepressant for each patient. The process involves the analysis of a patient blood sample to predict the individual response to various medications. It is based on a brain-in-a-dish model that allows high-throughput screening of available drugs and machine learning to identify the most effective choice in a fast and effortless way.


Net EU contribution
€ 2 499 000,00
126 Yigal Alon Street
6744332 Tel Aviv

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 071 000,00